Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: J Magn Reson Imaging. 2020 Oct 31;53(2):628–639. doi: 10.1002/jmri.27393

Table 1:

Clinical findings from the 23 patients with prostate lesions included in this study.

Subject Age PI-RADS v2 lesion score Radiologic lesion location PSA (ng/mL) Gleason Grade Group Pathology Specimen Type Clinical Risk Group

1 59 5 Right TZ and PZ 7.8 2 Biopsy (Systematic) FIR
2 54 5 Right PZ 10.6 3 Biopsy (Systematic), Radical Prostatectomy UIR
3 71 5 Right PZ and TZ 4.0 5 Biopsy (Systematic and Targeted), Radical Prostatectomy HR
4 72 5 Right PZ 5.7 2 Biopsy (Systematic) UIR
5 54 5 Right PZ 7.3 3 Biopsy (Systematic), Radical Prostatectomy HR
6 63 5 Right PZ 16.8 3 Biopsy (Systematic), Radical Prostatectomy HR
7 74 5 Right PZ 29.3 5 Biopsy (Systematic) HR
8 53 4 Left PZ 8.0 1 Biopsy (Systematic), Radical Prostatectomy FIR
9 66 4 Right PZ 8.7 3 Biopsy (Systematic and Targeted) UIR
10 67 5 Left PZ 4.6 2 Biopsy (Systematic and Targeted) FIR
11 62 5 Left PZ 14.0 3 Biopsy (Systematic), Radical Prostatectomy HR
12 74 4 Left PZ 4.4 3 Biopsy (Systematic and Targeted), Radical Prostatectomy UIR
13 50 3 Left PZ 4.3 2 Biopsy (Systematic), Radical Prostatectomy HR
14 65 4 Right TZ 8.0 1 Biopsy (Systematic) LR
15 81 5 Anterior TZ 8.5 2 Biopsy (Systematic and Targeted) FIR
16 77 5 Right PZ 3.5 4 Biopsy (Systematic), Radical Prostatectomy HR
17 70 4 Left PZ 7.4 2 Biopsy (Systematic and Targeted) FIR
18 58 4 Left PZ 7.4 2 Biopsy (Systematic), Radical Prostatectomy UIR
19 62 4 Left PZ 5.0 1 Biopsy (Systematic) LR
20 68 4 Right PZ 5.9 5 Biopsy (Systematic and Targeted), Radical Prostatectomy HR
21 64 5 Midline to Right TZ 8.6 2 Biopsy (Systematic and Targeted) FIR
22 51 5 Diffuse PZ 33.0 5 Biopsy (Systematic) VHR
23 51 3 Right TZ 5.4 3 Biopsy (Systematic), Radical Prostatectomy UIR

PI-RADS v2: Prostate Imaging – Reporting and Data System, version 2; PZ: peripheral zone of the prostate; TZ: transition zone of the prostate; PSA: prostate-specific antigen; FIR: Favorable intermediate risk; UIR: Unfavorable intermediate risk; HR: High risk; VHR: Very high risk.